The Real World Evidence (RWE) Solutions Market is expected to be around US$ 3.60 Billion by 2028 at a CAGR of 14% in the given forecast period.
The real world evidence solutions market is projected to rise majorly during the forecast period with the support from regulatory agencies for the utilization of RWE solutions. Using traditional pharmacovigilance methods and latest digital aids, regulators deploy real world evidence to monitor the safety of marketed drugs. Legislators are also beginning to realize the prominence of real world evidence. It further stimulates the patient-centered medication research and has enhanced the design and review of clinical trials. As a result of these changes, the global real world evidence solutions market is growing. In addition to this, the market growth is anticipated to be fueled by drug development delays resulting in a subsequent increase in development costs.
The global Real World Evidence (RWE) Solutions market is segregated on the basis of Component as Services, Data Sets, Clinical setting data, Claims data, Pharmacy data and Patient powered data. Based on Therapeutic area the global Real World Evidence (RWE) Solutions market is segmented in Oncology, Cardiovascular, Neurology, Immunology and Others. Based on End Users the global Real World Evidence (RWE) Solutions market is segmented in Pharmaceutical and Medical Devices Companies, Healthcare Providers, Healthcare Payers and Other End Users.
The global Real World Evidence (RWE) Solutions market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Real World Evidence (RWE) Solutions market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.
Competitive Rivalry
Anthem Inc., Clinigen Group plc, Cognizant Technology Solutions Corporation, IBM Corporation, ICON plc, IQVIA, Optum, Oracle Corporation, PAREXEL International Corporation, PerkinElmer Inc., PPD Inc., SAS Institute Inc., Syneos Health Inc., Pharmaceutical Product Development, LLC, Medpace Holdings, and others are among the major players in the global Real World Evidence (RWE) Solutions market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The Real World Evidence (RWE) Solutions Market has been segmented as below:
Real World Evidence (RWE) Solutions Market, By Component
Real World Evidence (RWE) Solutions Market, By Therapeutic area
Real World Evidence (RWE) Solutions Market, By End Users
Real World Evidence (RWE) Solutions Market, By Region
Real World Evidence (RWE) Solutions Market, By Company
The report covers:
Report Scope:
The global Real World Evidence (RWE) Solutions market report scope includes detailed study covering underlying factors influencing the industry trends. The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies. The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Real World Evidence (RWE) Solutions market share. Major industry players with significant revenue share include Anthem Inc., Clinigen Group plc, Cognizant Technology Solutions Corporation, IBM Corporation, ICON plc, IQVIA, Optum, Oracle Corporation, PAREXEL International Corporation, PerkinElmer Inc., PPD Inc., SAS Institute Inc., Syneos Health Inc., Pharmaceutical Product Development, LLC, Medpace Holdings, and others.
Reasons to Buy this Report:
Customization
Customized report as per the requirement can be offered with appropriate recommendations.
Below are our new Reports :-
application-to-person (A2P) SMS market
Artificial Intelligence Chipsets Market
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Market Research Process
2.3. Research Data Analysis
2.3.1.1. Secondary Research
2.3.1.2. Primary Research
2.3.1.3. Models for Estimation
2.4. Market Size Estimation
2.4.1. Bottom-Up Approach- Segmental Market Analysis
2.4.2. Top-Down Approach- Parent Market Analysis
3. Executive Summary
4. Market Overview
4.1. Introduction
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. Porter’s Five Force Analysis
5. Real World Evidence (RWE) Solutions Market, By Component
5.1. Introduction
5.2. Services
5.2.1. Market Overview
5.2.2. Market Size and Forecast
5.3. Data Sets
5.3.1. Market Overview
5.3.2. Market Size and Forecast
5.4. Clinical setting data
5.4.1. Market Overview
5.4.2. Market Size and Forecast
5.5. Claims data
5.5.1. Market Overview
5.5.2. Market Size and Forecast
5.6. Pharmacy data
5.6.1. Market Overview
5.6.2. Market Size and Forecast
5.7. Patient powered data
5.7.1. Market Overview
5.7.2. Market Size and Forecast
6. Real World Evidence (RWE) Solutions Market, By Therapeutic area
6.1. Introduction
6.2. Oncology
6.2.1. Market Overview
6.2.2. Market Size and Forecast
6.3. Cardiovascular
6.3.1. Market Overview
6.3.2. Market Size and Forecast
6.4. Neurology
6.4.1. Market Overview
6.4.2. Market Size and Forecast
6.5. Immunology
6.5.1. Market Overview
6.5.2. Market Size and Forecast
6.6. Others
6.6.1. Market Overview
6.6.2. Market Size and Forecast
7. Real World Evidence (RWE) Solutions Market, By End Users
7.1. Introduction
7.2. Pharmaceutical and Medical Devices Companies
7.2.1. Market Overview
7.2.2. Market Size and Forecast
7.3. Healthcare Providers
7.3.1. Market Overview
7.3.2. Market Size and Forecast
7.4. Healthcare Payers
7.4.1. Market Overview
7.4.2. Market Size and Forecast
7.5. Other End Users
7.5.1. Market Overview
7.5.2. Market Size and Forecast
8. Real World Evidence (RWE) Solutions Market, By Geography
8.1. Introduction
8.2. North America
8.2.1. North America Real World Evidence (RWE) Solutions, By Component
8.2.2. North America Real World Evidence (RWE) Solutions, By Therapeutic area
8.2.3. North America Real World Evidence (RWE) Solutions, By End Users
8.3. Europe
8.3.1. Europe Real World Evidence (RWE) Solutions, By Component
8.3.2. Europe Real World Evidence (RWE) Solutions, By Therapeutic area
8.3.3. Europe Real World Evidence (RWE) Solutions, By End Users
8.4. Asia-Pacific
8.4.1. Asia-Pacific Real World Evidence (RWE) Solutions, By Component
8.4.2. Asia-Pacific Real World Evidence (RWE) Solutions, By Therapeutic area
8.4.3. Asia-Pacific Real World Evidence (RWE) Solutions, By End Users
8.5. Rest of the World
8.5.1. Rest of the World Real World Evidence (RWE) Solutions, By Component
8.5.2. Rest of the World Real World Evidence (RWE) Solutions, By Therapeutic area
8.5.3. Rest of the World Real World Evidence (RWE) Solutions, By End Users
9. Competitive Insights
9.1. Key Insights
9.2. Company Market Share Analysis
9.3. Strategic Outlook
9.3.1. Mergers & Acquisitions
9.3.2. New Product Developments
9.3.3. Portfolio/Production Capacity Expansions
9.3.4. Joint Ventures, Collaborations, Partnerships & Agreements
9.3.5. Others
10. Company Profiles
10.1. Anthem Inc.
10.1.1. Company Overview
10.1.2. Product/Service Landscape
10.1.3. Financial Overview
10.1.4. Recent Developments
10.2. Clinigen Group plc
10.2.1. Company Overview
10.2.2. Product/Service Landscape
10.2.3. Financial Overview
10.2.4. Recent Developments
10.3. Cognizant Technology Solutions Corporation
10.3.1. Company Overview
10.3.2. Product/Service Landscape
10.3.3. Financial Overview
10.3.4. Recent Developments
10.4. IBM Corporation
10.4.1. Company Overview
10.4.2. Product/Service Landscape
10.4.3. Financial Overview
10.4.4. Recent Developments
10.5. ICON plc
10.5.1. Company Overview
10.5.2. Product/Service Landscape
10.5.3. Financial Overview
10.5.4. Recent Developments
10.6. IQVIA
10.6.1. Company Overview
10.6.2. Product/Service Landscape
10.6.3. Financial Overview
10.6.4. Recent Developments
10.7. Optum
10.7.1. Company Overview
10.7.2. Product/Service Landscape
10.7.3. Financial Overview
10.7.4. Recent Developments
10.8. Oracle Corporation
10.8.1. Company Overview
10.8.2. Product/Service Landscape
10.8.3. Financial Overview
10.8.4. Recent Developments
10.9. PAREXEL International Corporation
10.9.1. Company Overview
10.9.2. Product/Service Landscape
10.9.3. Financial Overview
10.9.4. Recent Developments
10.10. PerkinElmer Inc.
10.10.1. Company Overview
10.10.2. Product/Service Landscape
10.10.3. Financial Overview
10.10.4. Recent Developments
10.11. PPD Inc.
10.11.1. Company Overview
10.11.2. Product/Service Landscape
10.11.3. Financial Overview
10.11.4. Recent Developments
10.12. SAS Institute Inc.
10.12.1. Company Overview
10.12.2. Product/Service Landscape
10.12.3. Financial Overview
10.12.4. Recent Developments
10.13. Syneos Health Inc.
10.13.1. Company Overview
10.13.2. Product/Service Landscape
10.13.3. Financial Overview
10.13.4. Recent Developments
10.14. Pharmaceutical Product Development, LLC
10.14.1. Company Overview
10.14.2. Product/Service Landscape
10.14.3. Financial Overview
10.14.4. Recent Developments
10.15. Medpace Holdings
10.15.1. Company Overview
10.15.2. Product/Service Landscape
10.15.3. Financial Overview
10.15.4. Recent Developments
The Real World Evidence (RWE) Solutions Market has been segmented as below:
Real World Evidence (RWE) Solutions Market, By Component
Real World Evidence (RWE) Solutions Market, By Therapeutic area
Real World Evidence (RWE) Solutions Market, By End Users
Real World Evidence (RWE) Solutions Market, By Region
Real World Evidence (RWE) Solutions Market, By Company
